Acumen Pharmaceuticals Inc (NASDAQ:ABOS) — Market Cap & Net Worth
Market Cap & Net Worth: Acumen Pharmaceuticals Inc (ABOS)
Acumen Pharmaceuticals Inc (NASDAQ:ABOS) has a market capitalization of $171.87 Million ($171.87 Million) as of May 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17104 globally and #3851 in its home market, demonstrating a -10.86% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Acumen Pharmaceuticals Inc's stock price $2.38 by its total outstanding shares 72212758 (72.21 Million). Analyse ABOS cash flow metrics to see how efficiently the company converts income to cash.
Acumen Pharmaceuticals Inc Market Cap History: 2021 to 2026
Acumen Pharmaceuticals Inc's market capitalization history from 2021 to 2026. Data shows change from $488.16 Million to $171.87 Million (-35.68% CAGR).
Index Memberships
Acumen Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #469 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1675 of 3165 |
Weight: Acumen Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Acumen Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Acumen Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
339.94x
Acumen Pharmaceuticals Inc's market cap is 339.94 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $488.16 Million | $1.44 Million | -$100.61 Million | 339.94x | N/A |
Competitor Companies of ABOS by Market Capitalization
Companies near Acumen Pharmaceuticals Inc in the global market cap rankings as of May 5, 2026.
Key companies related to Acumen Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Acumen Pharmaceuticals Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Acumen Pharmaceuticals Inc's market cap moved from $488.16 Million to $ 171.87 Million, with a yearly change of -35.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $171.87 Million | +12.80% |
| 2025 | $152.37 Million | +22.67% |
| 2024 | $124.21 Million | -55.21% |
| 2023 | $277.30 Million | -28.89% |
| 2022 | $389.95 Million | -20.12% |
| 2021 | $488.16 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Acumen Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $171.87 Million USD |
| MoneyControl | $171.87 Million USD |
| MarketWatch | $171.87 Million USD |
| marketcap.company | $171.87 Million USD |
| Reuters | $171.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target s… Read more